{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:25:37Z","timestamp":1791548737842,"version":"4.3.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T00:00:00Z","timestamp":1743379200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-025-03800-7","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:54:03Z","timestamp":1743400443000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["In vitro susceptibility of clinical Clostridioides difficile isolates in Israel to metronidazole, vancomycin, fidaxomicin, ridinilazole and ibezapolstat,"],"prefix":"10.1186","volume":"25","author":[{"given":"Orna","family":"Schwartz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maya","family":"Azrad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avi","family":"Peretz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,31]]},"reference":[{"issue":"6","key":"3800_CR1","first-page":"319","volume":"19","author":"BJ Gawey","year":"2023","unstructured":"Gawey BJ, Khanna S. Clostridioides difficile infection: landscape and Microbiome therapeutics. Gastroenterol Hepatol (N Y). 2023;19(6):319\u201328.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"14","key":"3800_CR2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa1910215","volume":"382","author":"AY Guh","year":"2020","unstructured":"Guh AY, Mu Y, Winston LG, Johnston H, Olson D, Farley MM, et al. Trends in U.S. Burden of clostridioides difficile infection and outcomes. N Engl J Med. 2020;382(14):1320\u201330.","journal-title":"N Engl J Med"},{"key":"3800_CR3","first-page":"175628482211343","volume":"15","author":"AM Seekatz","year":"2022","unstructured":"Seekatz AM, Safdar N, Khanna S. The role of the gut Microbiome in colonization resistance and recurrent clostridioides difficile infection. Th Adv Gastroenterol. 2022;15:17562848221134396.","journal-title":"Th Adv Gastroenterol"},{"key":"3800_CR4","doi-asserted-by":"crossref","unstructured":"van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A, Guery B et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect. 2021;27 Suppl 2:S1-S21.5.","DOI":"10.1016\/j.cmi.2021.09.038"},{"issue":"5","key":"3800_CR5","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cmi.2017.11.017","volume":"24","author":"CH Chilton","year":"2018","unstructured":"Chilton CH, Pickering DS, Freeman J. Microbiologic factors affecting clostridium difficile recurrence. Clin Microbiol Infect. 2018;24(5):476\u201382.","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"3800_CR6","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/2015\/934594","volume":"26","author":"GG Zhanel","year":"2015","unstructured":"Zhanel GG, Walkty AJ, Karlowsky JA, Fidaxomicin. A novel agent for the treatment of clostridium difficile infection. Can J Infect Dis Med Microbiol. 2015;26(6):305\u201312.","journal-title":"Can J Infect Dis Med Microbiol"},{"issue":"2","key":"3800_CR7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40265-022-01832-x","volume":"83","author":"AJ Gonzales-Luna","year":"2023","unstructured":"Gonzales-Luna AJ, Carlson TJ, Garey KW. Emerging options for the prevention and management of clostridioides difficile infection. Drugs. 2023;83(2):105\u201316.","journal-title":"Drugs"},{"issue":"6","key":"3800_CR8","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/ciad792","volume":"78","author":"PC Okhuysen","year":"2024","unstructured":"Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J, de Oliveira CM, et al. A randomized, Double-Blind, phase 3 safety and efficacy study of ridinilazole versus Vancomycin for treatment of clostridioides difficile infection: clinical outcomes with Microbiome and metabolome correlates of response. Clin Infect Dis. 2024;78(6):1462\u201372.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"3800_CR9","doi-asserted-by":"crossref","first-page":"5714","DOI":"10.1128\/AAC.02903-14","volume":"58","author":"W Weiss","year":"2014","unstructured":"Weiss W, Pulse M, Vickers R. In vivo assessment of Smt 19969 in a hamster model of clostridium difficile infection. Antimicrob Agents Chemother. 2014;58(10):5714\u20138.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"3800_CR10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1093\/jac\/dku324","volume":"70","author":"SD Baines","year":"2015","unstructured":"Baines SD, Crowther GS, Freeman J, Todhunter S, Vickers R, Wilcox MH. SMT19969 as a treatment for clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model. J Antimicrob Chemother. 2015;70(1):182\u20139.","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"3800_CR11","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/jac\/dky135","volume":"73","author":"DR Snydman","year":"2018","unstructured":"Snydman DR, McDermott LA, Thorpe CM, Chang J, Wick J, Walk ST, et al. Antimicrobial susceptibility and ribotypes of clostridium difficile isolates from a phase 2 clinical trial of ridinilazole (SMT19969) and Vancomycin. J Antimicrob Chemother. 2018;73(8):2078\u201384.","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"3800_CR12","doi-asserted-by":"crossref","first-page":"G227","DOI":"10.1152\/ajpgi.00046.2020","volume":"319","author":"X Qian","year":"2020","unstructured":"Qian X, Yanagi K, Kane AV, Alden N, Lei M, Snydman DR, et al. Ridinilazole, a narrow spectrum antibiotic for treatment of clostridioides difficile infection, enhances preservation of microbiota-dependent bile acids. Am J Physiol Gastrointest Liver Physiol. 2020;319(2):G227\u201337.","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"7","key":"3800_CR13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1093\/cid\/ciac096","volume":"75","author":"KW Garey","year":"2022","unstructured":"Garey KW, Mcpherson J, Dinh AQ, Hu C, Jo J, Wang W, et al. Efficacy, safety, pharmacokinetics, and Microbiome changes of Ibezapolstat in adults with clostridioides difficile infection: A phase 2a multicenter clinical trial. Clin Infect Dis. 2022;75(7):1164\u201370.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"3800_CR14","first-page":"2149","volume":"75","author":"B Murray","year":"2020","unstructured":"Murray B, Wolfe C, Marra A, Pillar C, Shinabarger D. In vitro activity of the novel antibacterial agent Ibezapolstat (ACX-362E) against clostridioides difficile. J Antimicrob Chemother. 2020;75(8):2149\u201355.","journal-title":"J Antimicrob Chemother"},{"key":"3800_CR15","unstructured":"Clinicaltrials.gov. ACX-362E [Ibezapolstat] for Oral Treatment of Clostridioides Difficile Infection. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT04247542?cond=C-difficile%26term=NCT04247542%26rank=1%26tab=results#outcome-measures"},{"key":"3800_CR16","unstructured":"Monegro AF, Muppidi V, Regunath H. Hospital-Acquired Infections. [Updated 2023 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK441857\/"},{"issue":"3","key":"3800_CR17","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1128\/JCM.01796-09","volume":"48","author":"D Griffiths","year":"2010","unstructured":"Griffiths D, Fawley W, Kachrimanidou M, Bowden R, Crook DW, Fung R, et al. Multilocus sequence typing of clostridium difficile. J Clin Microbiol. 2010;48(3):770\u20138.","journal-title":"J Clin Microbiol"},{"key":"3800_CR18","unstructured":"EUCAST breakpoints 2020. The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http:\/\/www.eucast.org. Breakpoint tables for interpretation of MICs and zone diameters Version 100. 2020."},{"key":"3800_CR19","doi-asserted-by":"crossref","first-page":"745383","DOI":"10.3389\/fmed.2021.745383","volume":"8","author":"X Meng","year":"2021","unstructured":"Meng X, Huang X, Peng Z, Wang Y, Liu S, Zeng C, et al. Antibiotic resistances and molecular characteristics of clostridioides difficile in ICUs in a teaching hospital from central South China. Front Med (Lausanne). 2021;8:745383.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"3800_CR20","doi-asserted-by":"crossref","first-page":"22135","DOI":"10.1038\/s41598-020-79123-2","volume":"10","author":"BAP Roxas","year":"2020","unstructured":"Roxas BAP, Roxas JL, Claus-Walker R, Harishankar A, Mansoor A, Anwar F, et al. Phylogenomic analysis of clostridioides difficile ribotype 106 strains reveals novel genetic Islands and emergent phenotypes. Sci Rep. 2020;10(1):22135.","journal-title":"Sci Rep"},{"key":"3800_CR21","doi-asserted-by":"crossref","first-page":"102142","DOI":"10.1016\/j.anaerobe.2019.102142","volume":"62","author":"TJ Carlson","year":"2020","unstructured":"Carlson TJ, Blasingame D, Gonzales-Luna AJ, Alnezary F, Garey KW. Clostridioides difficile ribotype 106: A systematic review of the antimicrobial susceptibility, genetics, and clinical outcomes of this common worldwide strain. Anaerobe. 2020;62:102142.","journal-title":"Anaerobe"},{"key":"3800_CR22","doi-asserted-by":"crossref","unstructured":"Cui Y, Zhang C, Jia Q, Gong X, Tan Y, Hua X An epidemiological surveillance study (2021\u20132022): detection of a high diversity of Clostridioides difficile isolates in one tertiary hospital in Chongqing, Southwest China. BMC Infect Dis. 2023;23(1):703.","DOI":"10.1186\/s12879-023-08666-2"},{"key":"3800_CR23","doi-asserted-by":"crossref","unstructured":"Rohana H, Azrad M, Nitzan O, Adler A, Binyamin D, Koren O et al. Characterization of clostridioides difficile strains, the disease severity, and the microbial changes they induce. J Clin Med. 2020;9(12):4099.","DOI":"10.3390\/jcm9124099"},{"key":"3800_CR24","doi-asserted-by":"publisher","first-page":"102542","DOI":"10.1016\/j.anaerobe.2022.102542","volume":"74","author":"M Brajerova","year":"2022","unstructured":"Brajerova M, Zikova J, Krutova M. Clostridioides difficile epidemiology in the middle and the Far East. Anaerobe. 2022;74:102542. https:\/\/doi.org\/10.1016\/j.anaerobe.2022.102542. Epub 2022 Feb 28. PMID: 35240336.","journal-title":"Anaerobe"},{"key":"3800_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.anaerobe.2018.05.009","volume":"53","author":"A Cheknis","year":"2018","unstructured":"Cheknis A, Johnson S, Chesnel L, Petrella L, Sambol S, Dale SE, et al. Molecular epidemiology of clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006\u20132009 to 2012\u20132015. Anaerobe. 2018;53:38\u201342.","journal-title":"Anaerobe"},{"key":"3800_CR26","doi-asserted-by":"crossref","unstructured":"Hong S, Putsathit P, George N, Hemphill C, Huntington PG, Korman TM et al. Laboratory-based surveillance of clostridium difficile infection in australian health care and community settings, 2013 to 2018. J Clin Microbiol. 2020 1;58(11):e01552\u201320.","DOI":"10.1128\/JCM.01552-20"},{"issue":"18","key":"3800_CR27","doi-asserted-by":"crossref","first-page":"6643","DOI":"10.1128\/AEM.01379-12","volume":"78","author":"V Romano","year":"2012","unstructured":"Romano V, Pasquale V, Krovacek K, Mauri F, Demarta A, Dumontet S. Toxigenic clostridium difficile PCR ribotypes from wastewater treatment plants in Southern Switzerland. Appl Environ Microbiol. 2012;78(18):6643\u20136.","journal-title":"Appl Environ Microbiol"},{"key":"3800_CR28","doi-asserted-by":"crossref","unstructured":"Jahangir Alam M, Walk ST, Endres BT, Basseres E, Khaleduzzaman M, Amadio J et al. Community environmental contamination of toxigenic clostridium difficile. Open Forum Infect Dis. 2017;4(1).","DOI":"10.1093\/ofid\/ofx018"},{"issue":"10","key":"3800_CR29","doi-asserted-by":"crossref","first-page":"e0034923","DOI":"10.1128\/aac.00349-23","volume":"1","author":"DR Snydman","year":"2023","unstructured":"Snydman DR, McDermott LA, Thorpe CM, Goldstein EJC, Schuetz AN, Johnson S, et al. A US-based National surveillance study for the susceptibility and epidemiology of clostridioides difficile isolates with special reference to ridinilazole: 2020\u20132021. Antimicrob Agents Chemother. 2023;1(10):e0034923.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3800_CR30","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/jac\/dkaa522","volume":"76","author":"DA Collins","year":"2021","unstructured":"Collins DA, Wu Y, Tateda K, Kim HJ, Vickers RJ, Riley TV. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of clostridioides difficile. Antimicrob Chemother. 2021;76(4):967\u201372.","journal-title":"Antimicrob Chemother"},{"issue":"1","key":"3800_CR31","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s13756-020-00815-5","volume":"9","author":"M Sholeh","year":"2020","unstructured":"Sholeh M, Krutova M, Forouzesh M, Mironov S, Sadeghifard N, Molaeipour L, et al. Antimicrobial resistance in clostridioides (Clostridium) difficile derived from humans: A systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):158.","journal-title":"Antimicrob Resist Infect Control"},{"issue":"3","key":"3800_CR32","doi-asserted-by":"crossref","first-page":"e0162123","DOI":"10.1128\/aac.01621-23","volume":"68","author":"E Bass\u00e8res","year":"2024","unstructured":"Bass\u00e8res E, Eubank TA, Begum K, Alam MJ, Jo J, Le TM, et al. Antibacterial activity of Ibezapolstat against antimicrobial-resistant clinical strains of clostridioides difficile. Antimicrob Agents Chemother. 2024;68(3):e0162123.","journal-title":"Antimicrob Agents Chemother"},{"key":"3800_CR33","doi-asserted-by":"crossref","unstructured":"Van Eijk E, Boekhoud IM, Kuijper EJ, Bos-Sanders IMJG, Wright G, Smits WK. Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile., Van Eijk E, Boekhoud IM, Kuijper EJ, Bos-Sanders IMJG, Wright G, Smits WK. Genome Location Dictates the Transcriptional Response to PolC Inhibition in Clostridium difficile. Antimicrob Agents Chemother. 2019;63(2):e01363\u201318.","DOI":"10.1128\/AAC.01363-18"},{"issue":"10","key":"3800_CR34","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1128\/AAC.01136-13","volume":"57","author":"EJC Goldstein","year":"2013","unstructured":"Goldstein EJC, Citron DM, Tyrrell KL, Merriam CV. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother. 2013;57(10):4872\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"3800_CR35","unstructured":"Gancarz D. Summit Therapeutics Provides Update on Ridinilazole Check Point Threat Extraction secured this document [Internet]. Available from: https:\/\/www.summittxinc.com"},{"key":"3800_CR36","doi-asserted-by":"publisher","unstructured":"Dvoskin S, Xu WC, Brown NC, Yanachkov IB, Yanachkova M, Wright GE. A novel agent effective against clostridium difficile infection. Antimicrob Agents Chemother. 2012;56(3). https:\/\/doi.org\/10.1128\/AAC.06097-11.","DOI":"10.1128\/AAC.06097-11"},{"key":"3800_CR37","doi-asserted-by":"publisher","unstructured":"Corbett D, Wise A, Birchall S, et al. In vitro susceptibility of clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficile. J Antimicrob Chemother. 2014;70(6). https:\/\/doi.org\/10.1093\/jac\/dkv006.","DOI":"10.1093\/jac\/dkv006"},{"key":"3800_CR38","doi-asserted-by":"publisher","unstructured":"Freeman J, Vernon J, Vickers R, Wilcox MH. Susceptibility of clostridium difficile isolates of varying antimicrobial resistance phenotypes to SMT19969 and 11 comparators. Antimicrob Agents Chemother. 2016;60(1). https:\/\/doi.org\/10.1128\/AAC.02000-15.","DOI":"10.1128\/AAC.02000-15"},{"key":"3800_CR39","doi-asserted-by":"publisher","unstructured":"Snydman DR, McDermott LA, Jenkins SG, et al. Epidemiologic Trends in Clostridium difficile Isolate Ribotypes in United States from 2010 to 2014. Open Forum Infect Dis. 2017;4 (suppl_1). https:\/\/doi.org\/10.1093\/ofid\/ofx163.973","DOI":"10.1093\/ofid\/ofx163.973"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03800-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-025-03800-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-025-03800-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T05:54:51Z","timestamp":1743400491000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-025-03800-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,31]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3800"],"URL":"https:\/\/doi.org\/10.1186\/s12876-025-03800-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5818289\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,31]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study adhered to the Declaration of Helsinki. Tzafon Medical Center, Poriya and W. Hirsch Regional Microbiology Laboratory Clalit Health Services, Haifa, Center - Edith Wolfson Medical Center, Holon, and South - Soroka University Medical Center, Be\u2019er Sheva. The local Ethics (Helsinki) Committee of Tzafon Medical Center, W. Hirsch Regional Microbiology Laboratory Clalit Health Services and Soroka University Medical Center approved the study (approval numbers-POR-0085-15, WOMC-0115-20, SOR-0307-20, respectively). The need for informed consent was waived by all three mentioned committees. All experiments were performed in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"209"}}